Patent?You are right. They don't have a patent yet. Why? Because they haven't enough evidence yet to get said patent for a repurposed drug. They have to prove that ifenprodil works for their new use for the drug. Just because it is sold elsewhere(Japan) doesn't mean in the end AGN won't get their method of use patent. Just because a drug is being sold in a particular dosage/form doesn't stop another company from applying for a repurposed patent or formulation. So yah, they don't have the patent yet because their data from their covid trial hasn't been released yet. By the way Japan is a drop in the bucket when Ifenprodil could be in demand all over the world. And by the way, there are legal ramifications for a drug company to sell a labelled drug for another purpose. Also physicians are obligated to only use labelled drugs for that which the label says it is intended to be used. These rules laws are pretty strict around the world.
The point is this. Stop talking about things like it's a done deal. It isn't. Far from it. This story is still pretty much alive.
Let me ask you this Bear. If their data comes back as being significantly helpful in reducing inflammation do you think they won't get their method of use patent?
If so, why not?
Waitng for your response Yogi.